These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31646838)

  • 21. Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase.
    Morgan RG
    Cancer; 1989 Mar; 63(6 Suppl):1008-12. PubMed ID: 2521810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triple negative breast cancer.
    Cetin I; Topcul M
    Asian Pac J Cancer Prev; 2014; 15(6):2427-31. PubMed ID: 24761842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perspective on the design and biochemical pharmacology of inhibitors of thymidylate synthetase.
    Santi DV
    J Med Chem; 1980 Feb; 23(2):103-11. PubMed ID: 6987403
    [No Abstract]   [Full Text] [Related]  

  • 24. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
    Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
    Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy.
    Saw RP; Morgan M; Koorey D; Painter D; Findlay M; Stevens G; Clarke S; Chapuis P; Solomon MJ
    Dis Colon Rectum; 2003 Feb; 46(2):192-202. PubMed ID: 12576893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biochemical and antitumor effects of 5,8-dideazaisopteroylglutamate, a unique quinazoline inhibitor of thymidylate synthase.
    Fernandes DJ; Bertino JR; Hynes JB
    Cancer Res; 1983 Mar; 43(3):1117-23. PubMed ID: 6825083
    [No Abstract]   [Full Text] [Related]  

  • 27. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel compound LingH2-10 inhibits the growth of triple negative breast cancer cells in vitro and in vivo as a selective inverse agonist of estrogen-related receptor α.
    Ning Y; Chen H; Du Y; Ling H; Zhang L; Chen L; Qi H; Shi X; Li Q
    Biomed Pharmacother; 2017 Sep; 93():913-922. PubMed ID: 28715872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer.
    Van Triest B; Peters GJ
    Oncology; 1999 Oct; 57(3):179-94. PubMed ID: 10545786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-grade and hormone-treated prostate cancer express high levels of thymidylate synthase.
    Inoue T; Segawa T; Shiraishi T; Yamada T; Kinukawa N; Yoshida T; Toda Y; Shimizu Y; Nakamura E; Kinoshita H; Kamoto T; Ogawa O
    BJU Int; 2006 Jul; 98(1):197-200. PubMed ID: 16831168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.
    Papamichael D
    Stem Cells; 2000; 18(3):166-75. PubMed ID: 10840069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flavin-Dependent Thymidylate Synthase as a New Antibiotic Target.
    Choi M; Karunaratne K; Kohen A
    Molecules; 2016 May; 21(5):. PubMed ID: 27213314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.
    Ferrero JM; Hardy-Bessard AC; Capitain O; Lortholary A; Salles B; Follana P; Herve R; Deblock M; Dauba J; Atlassi M; Largillier R
    Cancer; 2016 Oct; 122(20):3119-3126. PubMed ID: 27412268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro and in vivo inhibition of thymidylate synthase of human colon cancer by 5-fluorouracil.
    Peters GJ; Laurensse EJ; van Groeningen CJ; Meijer S; Pinedo HM
    Adv Exp Med Biol; 1989; 253A():439-45. PubMed ID: 2624224
    [No Abstract]   [Full Text] [Related]  

  • 35. Thymidylate synthase: a critical target in cancer therapy?
    Rustum YM
    Front Biosci; 2004 Sep; 9():2467-73. PubMed ID: 15353299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased mean corpuscular volume of erythrocytes predicts the response to metronomic cyclophosphamide, capecitabine and bevacizumab treatment: is it true for capecitabine treatment or more?
    Arslan C; Altundag K
    Breast; 2012 Aug; 21(4):612-3. PubMed ID: 22521754
    [No Abstract]   [Full Text] [Related]  

  • 37. Targeting the androgen receptor in triple-negative breast cancer.
    Gucalp A; Traina TA
    Curr Probl Cancer; 2016; 40(2-4):141-150. PubMed ID: 27816190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Lee SJ; Choi YL; Park YH; Kim ST; Cho EY; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):743-51. PubMed ID: 21170649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The correlation between thymidylate synthase expression and cytotoxicity of 5-fluorouracil in human cancer cell lines: study using polyclonal antibody against recombinant human thymidylate synthase].
    Okabe H; Tsujimoto H; Fukushima M
    Gan To Kagaku Ryoho; 1997 Apr; 24(6):705-12. PubMed ID: 9126308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thymidylate synthase as a target enzyme for the melanoma-specific toxicity of 4-S-cysteaminylphenol and N-acetyl-4-S-cysteaminylphenol.
    Prezioso JA; Wang N; Bloomer WD
    Cancer Chemother Pharmacol; 1992; 30(5):394-400. PubMed ID: 1505078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.